• Olivier Lairez, Pauline Fournier, Romain Itier, Bérengère Bachelet, Antoine Huart, and Eve Cariou.
• Department of Cardiology, Toulouse University Hospital, Toulouse, France; Cardiac Imaging Center, Toulouse University Hospital, Toulouse, France; Department of Nuclear Medicine, Toulouse University Hospital, France; Medical School, Toulouse III Paul Sabatier University, Toulouse, France. Electronic address: lairez.o@chu-toulouse.fr.
• Presse Med. 2024 Mar 1; 53 (1): 104223104223.

AbstractThis review proposes to look at the evolution of cardiomyopathy treatments in the light of advances in diagnostic techniques, which have enabled to move from a mechanistic to a phenotypic and then etiological approach. The article goes beyond the ejection fraction approach, and look at new therapies that target the pathophysiological pathways of cardiomyopathies, either by targeting the phenotype, or by targeting the etiology. The evolution of HCM treatments is detailed, culminating in the latest etiological treatments such as mavacamten in sarcomeric HCM, tafamidis in transthyretin cardiac amyloidosis and migalastat in Fabry disease. Myosin stimulators are reviewed in the treatment of DCM, before opening perspectives for gene therapy, which proposes direct treatment of the culprit mutation.Copyright © 2024 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

13 keywords...

hide…